Zhongwen Sun

Zhongwen Sun


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 June 2021 in Frontiers in Immunology
Verified
Journal Article
Open access
NFNanNan Fu
NanNan Fu
FXFang Xie
Fang Xie
ZSZhongwen Sun
Zhongwen Sun
QWQin Wang
Qin Wang
T Follicular helper (Tfh) cells, a unique subset of CD4+T cells, play an essential role in B cell development and the formation of germinal centers (GCs). Tfh differentiation depends on various factors including cytokines, transcription factors and multiple costimulatory molecules. Given that OX40 signaling is critical for costimulating T cell activation and function, its roles in regulating Tfh cells have attracted widespread attention. Recent data have shown that OX40/OX40L signaling can not only promote Tfh cell differentiation and maintain cell survival, but also enhance the helper function of Tfh for B cells. Moreover, upregulated OX40 signaling is related to abnormal Tfh activity that causes autoimmune diseases. This review describes the roles of OX40/OX40L in Tfh biology, including the mechanisms by which OX40 signaling regulates Tfh cell differentiation and functions, and their close relationship with autoimmune diseases.

17 March 2022 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
PTPeijun Tang
Peijun Tang
XCXingnian Chen
Xingnian Chen
JXJunchi Xu
Junchi Xu
YHYunlong Hu
Yunlong Hu
ZYZhijian Ye
Zhijian Ye
MWMei-ying Wu
Mei-ying Wu
Objective. Multidrug-resistant tuberculosis (MDR-TB) causes persistent infection and challenges tuberculosis control worldwide. T cell-mediated immunity plays a critical role in controlling Mycobacterium tuberculosis (Mtb) infection, and therefore, enhancing Mtb-specific T cell immune responses represents a promising therapeutic strategy against TB. Cytokine-induced killer (CIK) immunotherapy is based on autologous infusion of in vitro expanded bulk T cells, which include both pathogen-specific and nonspecific T cells from patient peripheral blood mononuclear cells (PBMC) into TB patients. Preclinical mouse studies have shown that the adoptive T cell therapy inhibited Mtb infection. However, the efficacy of CIK immunotherapy in the treatment of MDR-TB infection has not been evaluated in clinical trials. Methods. We performed a retrospective study of MDR-TB patients who received CIK immunotherapy in combination with anti-TB chemotherapy and those who had standard chemotherapy. Results. Our results showed that CIK immunotherapy in combination with anti-TB chemotherapy treatment increased the conversion rate of sputum smear and Mtb culture, alleviated symptoms, improved lesion absorption, and increased recovery. The kinetics of serology and immunology index monitoring data showed good safety profiles for the CIK treatment. Conclusion. Our study has provided strong evidence that CIK immunotherapy in combination with anti-TB chemotherapy is beneficial for MDR-TB patients. A multicenter clinical trial is warranted to evaluate CIK as a new immune therapy for MDR-TB.

1 March 2018
Verified
Journal Article
Closed access
FYFan Yang
Fan Yang
JDJiahui Du
Jiahui Du
JWJie Wu
Jie Wu
PYPuyu Yuan
Puyu Yuan
QSQian Su
Qian Su
ZSZhongwen Sun
Zhongwen Sun